{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:31:55Z","timestamp":1789421515719,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","award":["GR-2016\\u201302361279"],"award-info":[{"award-number":["GR-2016\\u201302361279"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejca.2025.116194","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:10:10Z","timestamp":1766164210000},"page":"116194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["PIK3CA mutations and first-line outcomes in endocrine-resistant HR+\/HER2- metastatic breast cancer: A multicentric real-world study."],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9130-8611","authenticated-orcid":false,"given":"Maria Vittoria","family":"Dieci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Vernaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Colangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Massa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Di Liso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Giarratano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Napetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Bonomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Zangh\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Bottosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Lazzarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Santarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Boscolo Bragadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Indraccolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.116194_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1020299707510","article-title":"Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database","volume":"76","author":"Anderson","year":"2002","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2025.116194_bib2","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116194_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.ejca.2025.116194_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104793","article-title":"The evolving landscape of hormone receptor-positive\/HER2-negative metastatic breast cancer (EVOLVE): an Italian Delphi consensus report","volume":"213","author":"Miglietta","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.ejca.2025.116194_bib5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2025.03.023","article-title":"the PALMARES-2 Study Group. Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive\/HER2-negative BC patients: results from the multicenter PALMARES-2 study","volume":"36","author":"Provenzano","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.116194_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101931","volume":"59","author":"Lambertini","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ejca.2025.116194_bib7","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ejca.2025.116194_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002201","article-title":"Mutational profile of metastatic breast cancers: a retrospective analysis","volume":"13","author":"Lefebvre","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2025.116194_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3759179","article-title":"A systematic review of the prevalence and diagnostic workup of PIK3CA mutations in HR+\/HER2- metastatic breast cancer","volume":"2020","author":"Anderson","year":"2020","journal-title":"Int J Breast Cancer"},{"issue":"33","key":"10.1016\/j.ejca.2025.116194_bib10","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","article-title":"Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer","volume":"29","author":"Miller","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2025.116194_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","article-title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2025.116194_bib12","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","article-title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","volume":"34","author":"Andr\u00e9","year":"2023","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2025.116194_bib13","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-21-3276","article-title":"Clinical significance of PIK3CA and ESR1 mutations in circulating tumor DNA: analysis from the MONARCH 2 study of abemaciclib plus fulvestrant","volume":"28","author":"Tolaney","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2025.116194_bib14","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall Survival with Inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejca.2025.116194_bib15","doi-asserted-by":"crossref","first-page":"e232","DOI":"10.1016\/j.clbc.2019.08.011","article-title":"A systematic literature review of the prognostic and predictive value of PIK3CA mutations in HR+\/HER2- metastatic breast cancer","volume":"20","author":"Mollon","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2025.116194_bib16","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/s41467-021-22605-2","article-title":"Genomic profile of advanced breast cancer in circulating tumour DNA","volume":"12","author":"Kingston","year":"2021","journal-title":"Nat Commun"},{"issue":"22","key":"10.1016\/j.ejca.2025.116194_bib17","doi-asserted-by":"crossref","first-page":"12246","DOI":"10.3390\/ijms252212246","article-title":"Molecular analysis of PIK3CA in metastatic hormone receptor-positive breast cancer in Chile: clinical and pathological insights","volume":"25","author":"Araya","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.ejca.2025.116194_bib18","article-title":"Prevalence of somatic PIK3CA mutations in hormone receptor-positive metastatic breast cancer: the Indian experience","volume":"42","author":"Goel","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2025.116194_bib19","article-title":"PIK3CA mutational status in tissue & plasma and clinicopathological features in HR+\/HER2- breast cancer patients","volume":"8","author":"Ter\u00e1n Brage","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.ejca.2025.116194_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101270","article-title":"PIK3CA mutation impact in prognosis of advanced HR+\/HER2-negative breast cancer patients: collaborative multicentric Argentinean real-world study (YOGA-B-01)","volume":"8","author":"Mando","year":"2023","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.ejca.2025.116194_bib21","doi-asserted-by":"crossref","first-page":"P5-13-16","DOI":"10.1158\/1538-7445.SABCS21-P5-13-16","article-title":"A real-world assessment of PIK3CA testing and alpelisib treatment patterns among metastatic breast cancer patients in a community oncology setting","volume":"82","author":"O'Shaughnessy","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.116194_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62664-1","article-title":"PIK3CA mutations in endocrine-resistant breast cancer","volume":"14","author":"Schagerholm","year":"2024","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ejca.2025.116194_bib23","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1158\/1078-0432.CCR-22-2115","article-title":"Biology and targetability of the extended spectrum of PIK3CA mutations detected in breast carcinoma","volume":"29","author":"Rugo","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2025.116194_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.116194_bib25","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","article-title":"Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer","volume":"25","author":"Browne","year":"2024","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.ejca.2025.116194_bib26","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1200\/JCO.2021.39.15_suppl.1068","article-title":"Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm)","volume":"39","author":"Rugo","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.116194_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1012391","article-title":"Real world outcomes with alpelisib in metastatic hormone receptor-positive breast cancer patients: a single institution experience","volume":"12","author":"Alaklabi","year":"2022","journal-title":"Front Oncol"},{"issue":"6466","key":"10.1016\/j.ejca.2025.116194_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aaw9032","article-title":"Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3K\u03b1 inhibitors","volume":"366","author":"Vasan","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.ejca.2025.116194_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.116194_bib30","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nature11154","article-title":"Sequence analysis of mutations and translocations across breast cancer subtypes","volume":"486","author":"Banerji","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.116194_bib31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature11017","article-title":"The landscape of cancer genes and mutational processes in breast cancer","volume":"486","author":"Stephens","year":"2012","journal-title":"Nature"},{"issue":"13","key":"10.1016\/j.ejca.2025.116194_bib32","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1158\/1538-7445.AM2018-5371","article-title":"The Metastatic Breast Cancer Project: partnering with patients to accelerate progress in cancer research","volume":"78","author":"Wagle","year":"2018","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2025.116194_bib33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13058-020-01284-9","article-title":"Frequency and spectrum of PIK3CA somatic mutations in breast cancer","volume":"22","author":"Mart\u00ednez-S\u00e1ez","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"7538","key":"10.1016\/j.ejca.2025.116194_bib34","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nature13948","article-title":"Convergent loss of PTEN leads to clinical resistance to a PI(3)K\u03b1 inhibitor","volume":"518","author":"Juric","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2025.116194_bib35","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1186\/s12885-022-10078-5","article-title":"PIK3CA mutation status, progression and survival in advanced HR+\/HER2- breast cancer: a meta-analysis of published clinical trials","volume":"22","author":"Fillbrunn","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2025.116194_bib36","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor\u2013positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2025.116194_bib37","doi-asserted-by":"crossref","first-page":"P1-18-18","DOI":"10.1158\/1538-7445.SABCS21-P1-18-18","article-title":"Real-world natural history data among patients with PIK3CA-mutant and PIK3CA-wild-type advanced breast cancer","volume":"82","author":"Razavi","year":"2022","journal-title":"Cancer Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925010809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T08:47:13Z","timestamp":1781686033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925010809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"alternative-id":["S0959804925010809"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116194","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PIK3CA mutations and first-line outcomes in endocrine-resistant HR+\/HER2- metastatic breast cancer: A multicentric real-world study.","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.116194","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116194"}}